TY - DATA T1 - Supplementary Material for: Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis PY - 2017/04/11 AU - Thoennissen G.B. AU - Görlich D. AU - Bacher U. AU - Aufenberg T. AU - Hüsken A.-C. AU - Hansmeier A.A. AU - Evers G. AU - Mikesch J.-H. AU - Fritz F. AU - Bokemeyer C. AU - Müller-Tidow C. AU - Stelljes M. AU - Mesters R.M. AU - Krug U. AU - Kropff M.H. AU - Thoennissen N.H. AU - Berdel W.E. UR - https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Autologous_Stem_Cell_Transplantation_in_Multiple_Myeloma_in_the_Era_of_Novel_Drug_Induction_A_Retrospective_Single-Center_Analysis/4859606 DO - 10.6084/m9.figshare.4859606.v1 L4 - https://ndownloader.figshare.com/files/8053421 L4 - https://ndownloader.figshare.com/files/8053430 L4 - https://ndownloader.figshare.com/files/8053439 KW - Autologous stem cell transplantation KW - Induction therapy KW - Melphalan high-dose chemotherapy KW - Multiple myeloma KW - Novel compounds KW - Tandem autologous stem cell transplantation N2 - Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies. ER -